CJC-1295 / Ipamorelin Guide: Dosage, Stack, and What to Expect

The CJC-1295 / ipamorelin stack is the most popular growth hormone peptide combination in the research peptide community. Two peptides, two different mechanisms, and a synergistic effect on growth hormone release that's larger than either produces alone. This guide covers what each peptide actually does, why people stack them, how the most common protocols work, what side effects to watch for, and -- importantly -- what the published evidence does and doesn't say. Most of what you'll read about this stack online is anecdote-heavy and citation-light. This is the version with the citations.

Important Context Before You Read Further

CJC-1295 and ipamorelin are not FDA-approved for human use in the United States. They're sold legally as research chemicals -- meaning the chemicals themselves aren't illegal, but they're not regulated as medications, not produced under pharmaceutical-grade GMP standards by default, and have no FDA-approved indication. Some compounding pharmacies briefly offered them under specific protocols; many of those have since been restricted or removed.

What that means practically:

• Quality varies dramatically by supplier. Sterility, purity, and actual peptide content are not guaranteed.
• Long-term human safety data is limited. Most efficacy data comes from short-duration trials, typically 4--12 weeks.
• Use is at your own risk. This guide describes what's been studied and what users report. It is not a recommendation.

If you're considering a clinically supervised growth hormone peptide protocol, sermorelin and tesamorelin are FDA-approved alternatives (tesamorelin specifically for HIV-related lipodystrophy, sermorelin formerly for pediatric GH deficiency before being discontinued). Both work through the same GHRH-receptor pathway as CJC-1295.

What Each Peptide Does

To understand why people stack these two, it helps to understand what each one does on its own.

CJC-1295: The GHRH Analog

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary gland to make and release growth hormone. Native GHRH has a half-life of just a few minutes -- the body releases it in pulses, the pituitary responds, and the signal fades quickly.

CJC-1295 modifies the natural GHRH structure to resist enzymatic breakdown. There are two versions:

• CJC-1295 with DAC (Drug Affinity Complex): binds to albumin in the bloodstream, extending its half-life to roughly 6--8 days. Produces sustained elevation of GH baseline.
• CJC-1295 without DAC (also called Mod GRF 1-29): half-life around 30 minutes. Produces sharp, pulsatile GH spikes that mimic the natural rhythm.

Most modern stacks use the no-DAC version because the pulsatile pattern of GH release is what the body is built around. Sustained, non-pulsatile GH elevation (like from synthetic HGH or DAC-version peptides) appears to be biologically less normal and may carry different risks over time.

Ipamorelin: The Selective GHRP

Ipamorelin is a growth hormone releasing peptide (GHRP) -- a small synthetic peptide that activates the ghrelin receptor (GHSR-1a). Ghrelin and ghrelin-mimicking peptides also stimulate GH release, but through a different pathway than GHRH.

What sets ipamorelin apart from older GHRPs (like GHRP-2 or GHRP-6) is its selectivity. It activates GH release but does not meaningfully raise cortisol or prolactin in human studies. GHRP-6, for comparison, raises GH but also significantly increases hunger and to a lesser degree cortisol. Ipamorelin's clean profile is the main reason it became the GHRP of choice for combination protocols.

Why Stack Them?

GHRH and GHRPs activate GH release through different mechanisms. When given together, the effect is synergistic, not additive -- combined doses produce GH spikes substantially larger than either peptide alone at equivalent total dose. The GHRH pulse "primes" the pituitary, and the GHRP signals strongly through the ghrelin pathway at the same time.

This is well-documented pharmacologically and is the basis for clinical GHRH+GHRP combination testing in research.

How the Stack Is Typically Dosed

Below are dosing patterns that show up most consistently across published research and user-reported protocols. These are not medical recommendations.

The reason for the multi-times-per-day frequency is that the no-DAC version is short-acting -- a single dose produces a single GH pulse. To approximate the body's natural pattern of multiple GH pulses across a 24-hour cycle (with the largest pulse at deep sleep onset), some protocols do morning, post-workout, and pre-bed doses.

Why Pre-Bed Matters

The largest natural GH pulse occurs roughly 60--90 minutes after sleep onset. Stacking CJC-1295 and ipamorelin pre-bed augments that pulse, which is why almost every protocol includes a pre-bed dose even if other timings vary.

Why Empty Stomach

Both peptides work through pathways that are blunted by elevated blood glucose and circulating insulin. Eating a meal -- especially one with carbohydrates -- within 60--90 minutes before or after dosing reduces the GH response. Most users dose pre-bed at least 2 hours after dinner, and morning doses before breakfast.

What Users Actually Report

Anecdotal reports cluster around a few common observations. These are subjective effects from forum and user-survey data, not blinded trial endpoints:

• Improved sleep quality -- specifically, deeper sleep and waking up more rested. This is one of the most consistently reported effects, likely tied to the pre-bed GH pulse augmentation.
• Slightly improved recovery -- soreness from training resolves a little faster, though not dramatically.
• Skin and hair changes -- some users report fuller hair, slightly improved skin texture, and minor cosmetic effects after 8--12 weeks. Highly variable.
• Modest body composition changes -- small reductions in body fat and slight muscle preservation during cuts. Less dramatic than many marketing claims suggest.
• Increased appetite -- common but milder than with GHRP-6 or other less-selective GHRPs.
• Joint stiffness or aches -- a known signal of elevated IGF-1 and water retention.

What users don't report consistently: dramatic muscle gain, dramatic fat loss, performance changes anywhere near anabolic steroid territory, or anti-aging miracles. The realistic profile is "mild and gradual," not "transformational."

Side Effects and Risks

The reported side effect profile is mostly mild, but not nothing. Watch for:

• Injection site reactions -- flushing, warmth, mild redness for 5--15 minutes post-injection. Common, usually resolves on its own.
• Head rush / lightheadedness -- a tingly, slightly dizzy sensation right after injection that fades within minutes. Common in early weeks, often resolves with continued use.
• Water retention -- mild, usually 1--3 lbs. Most noticeable in the face and hands.
• Joint stiffness -- can develop after several weeks of consistent use. May indicate IGF-1 running high.
• Numbness or tingling in fingers/extremities -- a known signal of elevated GH/IGF-1 and possible early carpal-tunnel-type symptoms. Reduce dose or stop and reassess.
• Increased blood glucose -- GH is counter-regulatory to insulin. People with prediabetes or diabetes should be cautious, and labs should track this.

Long-term risks are not well characterized in humans. Theoretical concerns include sustained IGF-1 elevation (which has been associated in some epidemiological studies with cancer growth, though causation is debated), insulin resistance, and pituitary feedback effects. Most published trials are 4--12 weeks. There are not robust 2-year or 5-year human safety datasets for this stack.

What to Track

If you're going to use this stack, track it like a clinical trial of one. The peptide itself is uncontrolled enough that the only way to know whether it's doing something is to have your own baseline and follow-up data.

Before starting:

• Comprehensive metabolic panel
• IGF-1 (the most direct biomarker for GH activity)
• Fasting glucose and HbA1c
• Lipid panel
• Body weight, body composition if you can get it
• Subjective sleep quality, recovery, energy -- write down baselines

Every 4--8 weeks while on:

• IGF-1 (a meaningful elevation is the proof the peptide is doing what it claims)
• Fasting glucose
• Notes on subjective effects

Tracking each dose:

• Date, time, peptide name, dose in mcg
• Site (rotate -- abdomen, thighs, flanks)
• Anything notable (head rush severity, sleep that night, soreness)

This is exactly the kind of multi-variable, multi-medication tracking that injection-tracker apps were built for. DoneDose stores reconstitution math, schedules, site rotation, and biomarker notes in one place -- our best peptide tracker app guide covers a few options.

CJC-1295 vs Ipamorelin: Which Alone?

People sometimes ask whether they need both peptides or could run just one. The honest answer:

• Ipamorelin alone produces a GH pulse, but a smaller one than the stack. Some people use it alone for sleep and mild recovery effects.
• CJC-1295 (no-DAC) alone also produces a pulse but tends to be less pronounced subjectively than ipamorelin alone.
• The stack is what most users feel. The synergy from combining the GHRH and GHRP pathways is the reason the protocol exists. If you're going to do this, do the stack.

CJC-1295 with DAC, used alone, produces sustained GH elevation rather than pulses -- a different physiological profile and one with more theoretical risk for receptor desensitization and IGF-1 saturation.

Common Mistakes

• Eating too close to dosing. Carbs and fats blunt GH release. Time food separately.
• Skipping the labs. Without IGF-1 data, you don't know whether the peptide is working or whether it's bunk.
• Cycling forever without breaks. Continuous use without off-cycles increases the risk of receptor desensitization and IGF-1 running too high.
• Buying from a sketchy source. Research peptide quality is wildly inconsistent. Buy from suppliers who publish certificates of analysis and have a track record.
• Treating it like steroids. It's not. The effects are subtle and gradual. Going up to "blast" doses doesn't deliver steroid-tier results -- it just raises side-effect risk.
• Skipping site rotation. Repeated daily injections in one spot cause local lipohypertrophy and inconsistent absorption. Rotate.
• Not tracking. Three months in, "I think it's helping" isn't useful data. Pre/post bloodwork and a real log are.

Final Note: This Is an Honest Assessment

The CJC-1295 / ipamorelin stack is the most popular growth hormone peptide protocol because it has a real mechanism, a real pharmacological synergy, and a benign-looking side effect profile in short-duration use. It's also unregulated, sold as a research chemical with no quality guarantees, and has no long-term human safety data. Most marketing around it is wildly overstated.

If you're using this stack with an experienced provider, baseline labs, regular IGF-1 monitoring, and a clean supplier, the realistic expectation is "modest improvements in sleep, recovery, and body composition over 8--12 weeks." If you're expecting dramatic transformation, the published evidence -- and most honest user reports -- don't support it.

The protocol that's worth running is one you can actually evaluate. That means tracking what you took, when, and what your labs did in response. The rest is wishful thinking with extra steps.